Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine.

Investigación y educación

Enviado por remote_content el Lun, 21/10/2024 - 08:43

Enfermedades infecciosas

Álvarez-Moreno C, Yomayusa-González N, Bravo-Ojeda JS, Chacón-Sarmiento J. 20/12/2021

Background
The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed. The objective of this study was to assess the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in these patients.

Read full article

Artículos que te pueden interesar

Enfermedades infecciosas

CA.Imaging manifestations of pulmonary melioidosis: a case series. Radiologia

Octubre 1, 2022

Enfermedades infecciosas

Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. Expert Rev Vaccines.

Noviembre 11, 2022

Enfermedades infecciosas

Genotypic, proteomic, and phenotypic approaches to decipher the response to caspofungin and calcineurin inhibitors in clinical isolates of echinocandin-resistant Candida glabrata. J Antimicrob Chemother.

Febrero 23, 2022

21 Octubre, 2024